Увійти

Готові списки джерел за темами / P01A / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: P01A.

Статті в журналах з теми "P01A"

Автор: Grafiati

Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "P01A".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Gleave, M. E., K. N. Chi, L. Goldenberg, J. Chin, E. Winquist, L. Klotz, F. Saad, and J. Trachtenberg. "Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a)." Journal of Clinical Oncology 22, no. 14_suppl (July 15, 2004): 4635. http://dx.doi.org/10.1200/jco.2004.22.14_suppl.4635.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Gleave, M. E., K. N. Chi, L. Goldenberg, J. Chin, E. Winquist, L. Klotz, F. Saad, and J. Trachtenberg. "Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a)." Journal of Clinical Oncology 22, no. 14_suppl (July 15, 2004): 4635. http://dx.doi.org/10.1200/jco.2004.22.90140.4635.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

de Marco, Renato, and Maria Gerbase-DeLima. "P010." Human Immunology 75 (October 2014): 56. http://dx.doi.org/10.1016/j.humimm.2014.08.072.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Haarberg, Kelley M. K., Nancy D. Herrera, John J. Freidewald, Joseph R. Leventhal, Denis Glotz, and Anat R. Tambur. "P011." Human Immunology 75 (October 2014): 56. http://dx.doi.org/10.1016/j.humimm.2014.08.073.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Letwiniuk, Erica, Anne Halpin, Patricia Campbell, and Luis Hidalgo. "P012." Human Immunology 75 (October 2014): 57. http://dx.doi.org/10.1016/j.humimm.2014.08.074.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Harville, Izabelle, Soumya Pandey, Bobbie Rhodes-Clark, and Terry Harville. "P013." Human Immunology 75 (October 2014): 57. http://dx.doi.org/10.1016/j.humimm.2014.08.075.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Hidalgo, Luis G., Susan Hasenbank, Anne Halpin, and Patricia M. Campbell. "P014." Human Immunology 75 (October 2014): 58. http://dx.doi.org/10.1016/j.humimm.2014.08.076.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Ho, Eric K., Lloyd E. Ratner, David J. Cohen, Lingzhi Li, Xiuwei Tang, Raphael A. Clynes, Nicole Suciu-Foca, George Vlad, and E. Rodica Vasilescu. "P015." Human Immunology 75 (October 2014): 59. http://dx.doi.org/10.1016/j.humimm.2014.08.077.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Igbokwe, Anne, Jason Payne, Dana Crumback, Tammi Whitted, James Cicciarelli, and Kevin Burns. "P016." Human Immunology 75 (October 2014): 59. http://dx.doi.org/10.1016/j.humimm.2014.08.078.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Jones, June A., Melissa E. Jeresano, Charles Swisko, and Annette M. Jackson. "P017." Human Immunology 75 (October 2014): 60. http://dx.doi.org/10.1016/j.humimm.2014.08.079.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Jindra, Peter, Jerome Saltarrelli, Christine O’Mahony, Charles Van Buren, Eva McKissick, Noriel Acorda, Alfred Eaton, et al. "P018." Human Immunology 75 (October 2014): 60. http://dx.doi.org/10.1016/j.humimm.2014.08.080.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Lan, James H., Michelle Hickey, Xiaohai Zhang, Elaine F. Reed, and Qiuheng Zhang. "P019." Human Immunology 75 (October 2014): 61. http://dx.doi.org/10.1016/j.humimm.2014.08.081.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Hampshire, Daniel J., Lisa D. Bloomer, Ahlam M. Al-Buhairan, Rachael E. Coyle, Raymon N. C. P. Vijzelaar, David Lillicrap, Paula D. James, et al. "Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease." Blood 116, no. 21 (November 19, 2010): 2218. http://dx.doi.org/10.1182/blood.v116.21.2218.2218.

Повний текст джерела

Анотація:

Abstract Abstract 2218 Introduction: Type 1 von Willebrand disease (VWD) results from a partial quantitative deficiency of von Willebrand factor (VWF). Three multicentre studies were recently conducted to elucidate the molecular and clinical features of type 1 VWD; undertaken in the European Union (EU), Canada and the UK. All three successfully identified genetic alterations likely to cause type 1 VWD, but failed to identify a genetic cause in approximately 30–40% of patients. To date, relatively little is known regarding the extent to which large-scale deletions or duplications of VWF contribute to the pathogenesis of type 1 VWD due to the difficulty in identifying such events in heterozygous individuals. The aim of this initial investigation, on behalf of the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD) and the EU study on VWD (EU-VWD), was to ascertain whether copy number variation (CNV) within VWF contributes to type 1 VWD phenotype in a cohort of index cases (IC) recruited by the EU study. Methods: Twenty-five mutation-negative IC and a further seven IC, in which the identified mutation did not explain the VWD phenotype, were investigated. Multiplex ligation-dependent probe amplification (MLPA), a well established technique based on sequence-specific probe hybridization to genomic DNA, was used to screen for CNV within VWF, utilizing a recently released VWF MLPA kit (P011-A1/P012-A1; MRC-Holland). In addition, five healthy control individuals (HC) were also screened. Fragment size analysis on an ABI 3730 DNA sequencer was followed by calculation of copy number ratios for each exon-specific amplicon in comparison with HC. Results: Analysis highlighted heterozygous CNV in 7/32 IC; five deletions and two apparent duplications. Regarding the deletions; three were the recently described in-frame deletion of exons 4 and 5 (p.Asp75_Gly178del; Sutherland et al., 2009), the other two patients both had a novel deletion of exons 32–34. Interestingly, the exon 32–34 deletion was also predicted to be in-frame (p.Arg1819_Cys1948delinsSer) and in both IC was associated with abnormal multimers (AbM) and low VWF:Ag (32 and 12 IU/dL respectively) and VWF:RCo (23 and 11 IU/dL respectively) levels. Deletions in all five cases segregated with disease phenotype. The two apparent duplications of exon 2 were both shown to be false positive results following further investigation with a new version of the MLPA kit (P011-B1/P012-B1). Conclusions: CNV of VWF has been shown to contribute to the pathogenesis of type 1 VWD. MLPA analysis of VWF has identified a previously described and a novel heterozygous deletion, both of which result in in-frame deletion of the VWF protein. The analysis also demonstrates that care must be taken when analyzing MLPA data to avoid false positive results. This adds to the mutations detected in the EU cohort, bringing the number to 113/150 IC (75%). Furthermore, MLPA analysis has increased the overall mutation detection rate in EU IC with AbM to 100%. These findings suggest that CNV is a significant contributor to mutation spectrum in type 1 VWD. Application of MLPA to the wider ZPMCB-VWD and EU-VWD patient cohorts will enable ascertainment of the contribution of large deletion/duplication events to all types of VWD pathogenesis. Disclosures: Vijzelaar: MRC-Holland b.v.: Employment.

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Chan, Wiley. "P012 The EHR." BMJ Quality & Safety 22, Suppl 1 (August 2013): A5.1—A5. http://dx.doi.org/10.1136/bmjqs-2013-002293.12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

O’Brien, William G., Isadora Susan Daniels, Zhaoyang Zhao, and Cheng Chi Lee. "P01." Cryobiology 69, no. 1 (August 2014): 195. http://dx.doi.org/10.1016/j.cryobiol.2014.06.053.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Wheeler, Lucy. "P019 Treating conjoined twins." Archives of Disease in Childhood 104, no. 7 (June 19, 2019): e2.22-e2. http://dx.doi.org/10.1136/archdischild-2019-nppc.29.

Повний текст джерела

Анотація:

SituationD and M are conjoined twins born without an antenatal diagnosis and assessed as not suitable for separation. At the time of admission they were 21 months old with a combined weight of 17.1 Kg. D presented unwell with a raised heart rate and respiratory rate. A working diagnosis of sepsis (possibly urinary tract infection) was made. Advice was sought from pharmacy on the doses of ceftriaxone and paracetamol. Peripheral intravenous (IV) access was only available in twin M.BackgroundThe twins are joined side by side from the upper chest to the pelvis. They have separate heads, three arms and 2 legs. They have 2 hearts with a fused aorta, a shared liver, 2 gallbladders, 2 stomachs, 3 kidneys and a single bladder. D has a complex congenital heart condition and a poor prognosis. On admission, D was receiving propranolol, but M was not. The dose was based on the combined weight of the twins divided by 2. Conjoined twins are a rare phenomenon, occurring 1 in 50,000 to 100,000 births.1 Around 60% of these are stillborn or die shortly after birth. There are many different types of join with differences in shared organs and limbs. Consequently each twin pair is almost unique and consideration must be given as to how medication is dosed according to pharmacokinetic principles.OutcomeOpinion of the multidisciplinary team was that the twins have relatively separate circulations, although some cross-circulation would be expected. On admission, saturations in the right arm (twin D) were 75%. On the left side (twin M) this was 95%. Ceftriaxone is a highly protein bound, hydrophilic antibiotic,2 The degree of cross circulation (how much blood volume is shared between the twins) would affect the volume of distribution and hypoalbuminaemia was likely to increase the apparent volume of distribution. Based on this, ceftriaxone dosing was advised on the combined weight of the twins and given at 50 mg/Kg to M only. Ceftriaxone is excreted mainly unchanged in the urine and bile with little renal clearance or hepatic metabolism so this was not a concern. After 2 days, Ds CRP had reduced and the twins were switched to oral amoxicillin. Dosing was based on the combined weight of the twins and each was given half the dose. As each twin has a separate stomach, it was assumed relatively individual enteral absorption occurs. Ds CRP continued to drop and the twins were discharged home on day 4 with a further 3 days of oral amoxicillin. Paracetamol dosing was advised at 15 mg/kg based on the combined weight and half given to each twin. As required use was agreed, as there was uncertainty over the amount of hepatic metabolism that would occur by the twins shared liver.Lessons learntConjoined twins are a complex yet interesting challenge in terms of medication dosage and administration. There is a lack of evidence and dosing has been based on pharmacokinetic principles and adjusted according to clinical response.ReferencesOwolobi AT, Oseni SB, Sowande OA, et al. Dicephalus dibrachius dipus conjoined twins in a triplet pregnancy. Tropical Journal of Obstetrics and Gynaecology 2005;22:87–88.Electronic Medicines Compendium: Rocephin 1g powder for solution for injection or infusion - Summary of Product Characteristics. http://www.emc.org.uk/(Accessed 12 Jun 2018)

Стилі APA, Harvard, Vancouver, ISO та ін.

17

D'Elia, A., M. P. Pighetti, F. V. Vanacore, and S. M. Saporito. "P015: Fetal neurological evaluation." Ultrasound in Obstetrics and Gynecology 22, S1 (2003): 74. http://dx.doi.org/10.1002/uog.473.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Al-sahmani, Mohammed, Irena Trnavska, Monika Antosova, Libuse Antosova, Jarmila Kissova, Hana Filkova, Jan Smetana, et al. "Prognostic Significance of Morphological Evaluation of Tumor Cells in Multiple Myeloma." Blood 114, no. 22 (November 20, 2009): 4889. http://dx.doi.org/10.1182/blood.v114.22.4889.4889.

Повний текст джерела

Анотація:

Abstract Abstract 4889 Multiple myeloma (MM) is the second most common hematological malignancy. It is caused by clonal proliferation of terminally differentiated cells of B-lineage. Morphology assessment including the determination of plasma cell percentage in the bone marrow remains one of the basic diagnostic procedures even in the era of genomics. The objective of this study was to evaluate the prognostic impact of the presence of different plasma cell morphological subtypes on overall treatment response and long-term survival. We also analyzed whether this parameter can be correlated to other conventional prognostic/predictive markers. Our cohort consisted of 139 newly diagnosed MM patients who subsequently underwent autologous transplantation (AT) within the 4W and CMG 2002 clinical trials in a single center. Percentage of plasma cell subtypes in the bone marrow was evaluated based on the progressive nucleolus analysis, assessment of nuclear chromatin, and the nucleus/cytoplasm (N/C) ratio. A combination of these elements permits differentiation of eight subtypes P000-P111 and four subclassifications. Mature plasma cells (P000, P001) were found in 42.4% of patients; type I proplasmocytes (P010, P011, P100) in 38.1% of patients; and type II proplasmocytes (P101, P110) in 19.4% of patients. For patients undergoing AT, there was a statistically significant association between the presence of P000 subtype and overall treatment response whereas group of patients with overall therapeutic response ORR has lower number of mature plasma cell (P000 subtype) than patients without treatment response (median 24.0% vs. 36.0%, p = 0.032). Patients with <10% bone marrow infiltration by mature plasmocytes (P000 subtype) had shorter overall survival compared with patients with P000 percentage of ≥37% (46.8 months vs. 77.8 months; p = 0.020). The presence of <3% proplasmocytes (P110 subtype) was associated with longer time to progression compared with P110 ≥31% infiltration (median: 54.6 months vs. 22.4 months; p=0.045). Patients in ISS stage 1 or 2 had lower percentage of P010 (type I) proplasmocytes than patients in stage 3 (11.5% vs. 23.0%; p=0.030). In contrast, higher infiltration of P100 (type I) proplasmocytes and P101 (type II) proplasmocytes was observed in patients in 1-2 ISS stage compared with stage 3 patients (12.0% vs. 6.5%; p=0.015 for P100 and 1.0% vs. 0.0%; p=0.046 for P101). Patients without deletion of 13q14 chromosome had higher bone marrow percentage of mature P000 plasmocytes than patients with deletion of 13q14 (35% vs. 13%; p=0.014). Deletion of 13q14 was also associated with lower number of type II P110 proplasmocytes (36.5% vs. 6.0%; p=0.012). Despite advances in high-tech genomic technologies, evaluation of plasmocyte infiltration of the bone marrow still belongs to basic diagnostic procedures in MM and further morphological subtyping of plasmocytes should provide important prognostic information for MM patients treated by autologous stem cell transplantation. Supported by grants MSM 0021622434, MŠMT LC06027, MZCR NR9225-3 and IGA NR9225-3. Disclosures No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Schippers, Timo, Keith Jarosinski, and Nikolaus Osterrieder. "The ORF012 Gene of Marek's Disease Virus Type 1 Produces a Spliced Transcript and Encodes a Novel Nuclear Phosphoprotein Essential for Virus Growth." Journal of Virology 89, no. 2 (November 12, 2014): 1348–63. http://dx.doi.org/10.1128/jvi.02687-14.

Повний текст джерела

Анотація:

ABSTRACTMarek's disease virus (MDV), an alphaherpesvirus, is the causative agent of a lethal disease in chickens characterized by generalized nerve inflammation and rapid lymphoma development. The extensive colinearity of the MDV genome with those of related herpesviruses has eased functional characterization of many MDV genes. However, MDV carries a number of unique open reading frames (ORFs) that have not yet been investigated regarding their coding potentials and the functions of their products. Among these unique ORFs are two putative ORFs, ORF011 and ORF012, which are found at the extreme left end of the MDV unique long region. Using reverse transcriptase PCR, we showed that ORF011 and ORF012 are not individual genes but form a single gene through mRNA splicing of a small intron, resulting in the novel ORF012. We generated an ORF012-null virus using an infectious clone of MDV strain RB-1B. The deletion virus had a marked growth defectin vitroand could not be passaged in cultured cells, suggesting an essential role for the ORF012 product in virus replication. Further studies revealed that protein 012 (p012) localized to the nucleus in transfected and infected cells, and we identified by site-directed mutagenesis and green fluorescent protein (GFP) reporter fusion assays a nuclear localization signal (NLS) that was mapped to a 23-amino-acid sequence at the protein's C terminus. Nuclear export was blocked using leptomycin B, suggesting a potential role for p012 as a nuclear/cytoplasmic shuttling protein. Finally, p012 is phosphorylated at multiple residues, a modification that could possibly regulate its subcellular distribution.IMPORTANCEMarek's disease virus (MDV) causes a devastating oncogenic disease in chickens with high morbidity and mortality. The costs for disease prevention reach several billion dollars annually. The functional investigation of MDV genes is necessary to understand its complex replication cycle, which eventually could help us to interfere with MDV and herpesviral pathogenesis. We have identified a previously unidentified phosphoprotein encoded by MDV ORF012. We were able to show experimentally that predicted splicing of the gene based on bioinformatics data does indeed occur during replication. The newly identified p012 is essential for MDV replication and localizes to the nucleus due to the presence of a transferable nuclear localization signal at its C terminus. Our results also imply that p012 could constitute a nucleocytoplasmic shuttle protein, a feature that could prove interesting and important.

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Badgery, W. B., G. D. Millar, D. L. Michalk, P. Cranney, and K. Broadfoot. "The intensity of grazing management influences lamb production from native grassland." Animal Production Science 57, no. 9 (2017): 1837. http://dx.doi.org/10.1071/an15866.

Повний текст джерела

Анотація:

The intensity of grazing management required for optimal pasture and animal production from heterogeneous native grasslands has received little research in the high-rainfall zone of south-eastern Australia. The aim of this experiment was to determine how the intensity of grazing management, from continuous grazing (P01) to flexible 4- and 20-paddock rotational systems (P04 and P20), influenced the productivity and sustainability of a Merino ewe, terminal sire lamb production system run on a native grassland dominated by Microlaena stipoides and Rytidosperma spp. The present paper focuses on the animal production and feed-quality results from this experiment. There was a higher per head animal production for the P01 than the P20, with the P04 being intermediate. The differences were found for ewe liveweight and fat score, lamb growth rates and lamb liveweight at weaning. The P20 was able to run higher ewe numbers, in response to greater feed on offer than for P04 and P01, which enabled lamb production per hectare at weaning to be similar and greasy wool production per hectare to be greater than for P01. The organic matter digestibility of the ewe diet estimated from faecal analysis was lower for P20 and P04 systems than for P01 over a 7-month period and explained differences measured in sheep performance at that time. When lambs were retained after weaning, they could be kept for longer on the P20 and grown to a greater weight than for the P01 and P04, but the criteria for setting stocking rates and selling lambs from systems influenced the production from the systems. Further work is needed to investigate the interaction between stocking rate (ewe numbers and lamb sale time) and grazing management and examine different options for managing rotational grazing systems.

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Michael, C., and T. Witharanage. "P015: Ertapenem induced visual hallucinations." European Geriatric Medicine 5 (September 2014): S87. http://dx.doi.org/10.1016/s1878-7649(14)70193-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Ramanathan, Chakkedath. "P012: Nasal Trauma: Halifax Survey." Otolaryngology–Head and Neck Surgery 135, no. 2_suppl (August 2006): P218. http://dx.doi.org/10.1016/j.otohns.2006.06.1043.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

El-Matary, W., S. Girgis, H. Huynh, J. Turner, and B. Diederichs. "P019 MICROSCOPIC COLITIS IN CHILDREN." Journal of Crohn's and Colitis Supplements 3, no. 1 (September 2009): 7. http://dx.doi.org/10.1016/s1873-9954(09)70033-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Sauna, A., A. Bongiovanni, F. Mollica, M. Motta, A. Sapuppo, M. Papale, L. Tardino, G. F. Parisi, M. Spina, and S. Leonardi. "P014 VACTERL association: case report." Digestive and Liver Disease 50, no. 4 (October 2018): e364. http://dx.doi.org/10.1016/s1590-8658(18)31013-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Kandolf Sekulović, L., T. Radević, M. Rajović, M. Dinić, L. Zolotarevski, Z. Mijušković, R. Zečević, and M. Novaković. "P019. Melanoma in Balkan region." Melanoma Research 21 (June 2011): e27. http://dx.doi.org/10.1097/01.cmr.0000399480.31979.8e.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Hicks, Janet. "P014: Look for the rainbow." European Journal of Surgical Oncology 46, no. 6 (June 2020): e14. http://dx.doi.org/10.1016/j.ejso.2020.03.053.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Susi Susanti Kaban, R.Edhy Mirwandhono, and Hasnudi. "PENGGUNAAN TEPUNG LIMBAH UDANG DENGAN PENGOLAHAN FILTRAT AIR ABU SEKAM, FERMENTASI EM-4 DAN KAPANG Trichoderma viride PADA RANSUM TERHADAP PERTUMBUHAN AYAM BROILER." Jurnal Peternakan Integratif 2, no. 3 (February 28, 2015): 321–31. http://dx.doi.org/10.32734/jpi.v2i3.2734.

Повний текст джерела

Анотація:

Penelitian ini bertujuan untuk mengetahui sejauh mana pengaruh penggunaan tepung limbah udang(TLU) dengan pengolahan filtrat air abu sekam (FAAS), fermentasi EM-4 dan kapang Trichoderma viride(TV)dalam ransum terhadap pertambahan bobot badan, konsumsi ransum dan konversi ransum ayam broiler.Rancangan yang dipakai adalah rancangan acak lengkap dengan 8 perlakuan dan 3 ulangan selanjutnyadianalisis dengan pembanding ortogonal kontras. Perlakuan terdiri P0a(Ransumkomersil), P0b(0% TLU),P1(5%TLU FAAS), P2(5% TLU EM4), P3(5% TLU TV),P4(10% TLU FAAS), P5(10% TLU EM4), P6(10% TLUTV). Parameter yang diteliti adalah konsumsi ransum, pertambahan bobot badan dan konversi ransum. Hasilpenelitian menunjukkan rataan konsumsi (g/ekor/hari) P0a:90,85, P0b:80,22, P1:80,63, P2:80,02, P3:81,13,P4:77,15, P5:78,54 dan P6:78,87. Rataan pertambahan bobot badan (g/ekor/hari) P0a:52,34, P0b:42,09,P1:41,52, P2:41,61, P3:42,17, P4:38,90, P5:39,91 danP6:40,33. Rataan konversi ransum P0a:1,74, P0b:1,91,P1:1,94, P2:1,93, P3:1,92, P4:1,99, P5:1,97 dan P6:1,96. Kesimpulan dari penelitian ini adalah penggunaantepung limbah udang dengan pengolahan filtrat air abu sekam, fermentasi EM4 dan kapang Trichoderma viridedapat meningkatkan pertambahan bobot badan, konsumsi ransum dan memperbaiki konversi ransum pada levelpemakaian 5% pada ransum, namun belum dapat mengimbangi penggunaan ransum komersil dalammeningkatkan pertambahan bobot badan, konsumsi ransum dan memperbaiki konversi ransum ayam broiler.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Susi Susanti Kaban, R.Edhy Mirwandhono, and Hasnudi. "PENGGUNAAN TEPUNG LIMBAH UDANG DENGAN PENGOLAHAN FILTRAT AIR ABU SEKAM, FERMENTASI EM-4 DAN KAPANG Trichoderma viride PADA RANSUM TERHADAP PERTUMBUHAN AYAM BROILER." Jurnal Peternakan Integratif 2, no. 3 (February 28, 2015): 321–31. http://dx.doi.org/10.32734/jpi.v2i3.2734.

Повний текст джерела

Анотація:

Penelitian ini bertujuan untuk mengetahui sejauh mana pengaruh penggunaan tepung limbah udang(TLU) dengan pengolahan filtrat air abu sekam (FAAS), fermentasi EM-4 dan kapang Trichoderma viride(TV)dalam ransum terhadap pertambahan bobot badan, konsumsi ransum dan konversi ransum ayam broiler.Rancangan yang dipakai adalah rancangan acak lengkap dengan 8 perlakuan dan 3 ulangan selanjutnyadianalisis dengan pembanding ortogonal kontras. Perlakuan terdiri P0a(Ransumkomersil), P0b(0% TLU),P1(5%TLU FAAS), P2(5% TLU EM4), P3(5% TLU TV),P4(10% TLU FAAS), P5(10% TLU EM4), P6(10% TLUTV). Parameter yang diteliti adalah konsumsi ransum, pertambahan bobot badan dan konversi ransum. Hasilpenelitian menunjukkan rataan konsumsi (g/ekor/hari) P0a:90,85, P0b:80,22, P1:80,63, P2:80,02, P3:81,13,P4:77,15, P5:78,54 dan P6:78,87. Rataan pertambahan bobot badan (g/ekor/hari) P0a:52,34, P0b:42,09,P1:41,52, P2:41,61, P3:42,17, P4:38,90, P5:39,91 danP6:40,33. Rataan konversi ransum P0a:1,74, P0b:1,91,P1:1,94, P2:1,93, P3:1,92, P4:1,99, P5:1,97 dan P6:1,96. Kesimpulan dari penelitian ini adalah penggunaantepung limbah udang dengan pengolahan filtrat air abu sekam, fermentasi EM4 dan kapang Trichoderma viridedapat meningkatkan pertambahan bobot badan, konsumsi ransum dan memperbaiki konversi ransum pada levelpemakaian 5% pada ransum, namun belum dapat mengimbangi penggunaan ransum komersil dalammeningkatkan pertambahan bobot badan, konsumsi ransum dan memperbaiki konversi ransum ayam broiler.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Baer, H. M., E. MacDonald, A. Ferguson, A. M. Scott, M. I. Khan, K. A. Bain, U. Z. Ijaz, et al. "P014 Identification of Crohn’s disease immunopathotypes." Journal of Crohn's and Colitis 14, Supplement_1 (January 2020): S137. http://dx.doi.org/10.1093/ecco-jcc/jjz203.143.

Повний текст джерела

Анотація:

Abstract Background Crohn’s disease (CD) is a chronic inflammatory gastrointestinal condition, with globally increasing incidence. Patients with CD suffer from a loss of tolerance towards their commensal microbiota causing an aberrant immune response, occurring in a protracted relapse and remission cycle. Although a variety of frontline therapies is currently available, including targeted therapies such as biologic drugs, 30–40% of CD patients still require surgery to manage the disease. At present, the immunobiology of CD is not fully understood. However, differences in immune responses between patients might play an important role in diverse treatment responses. The aim of this study was to identify differences in peripheral and local immune responses of CD to understand differences in disease behaviour and treatment outcome. Methods Peripheral blood mononuclear cells and plasma were isolated from whole blood of a cross-sectional CD patient cohort (nCD = 12) and normal controls (NC, nNC = 28). Flow cytometry analysis and multiplex assays were used to quantify immune cell populations and cytokine levels, respectively. The local immune response was analysed by bulk RNA sequencing of mucosal colonic biopsies either from inflamed CD or normal tissue. Gene signatures were then followed up by validation in publicly deposited gene expression datasets (nCD = 36, nNC = 24), and by measurement of specific proteins using our archived samples. Results Peripheral immunophenotyping of the initial cross-sectional study displayed three different types of CD patients, characterised by either a decrease in leukocyte populations, an increase of cytokines, or a change in both. Analysis of the RNAseq data derived from colonic biopsies revealed four distinct clusters in genes associated with the immune response in CD patients. Further pathway analysis showed one cluster with an enriched B cell signature and another cluster with an elevated macrophage and neutrophil response. We utilised publicly available gene expression datasets to validate these signatures in a larger cohort and identified a selection of patients with an up-regulated pro-inflammatory macrophage response. Using correlation analysis, we suggest an immunopathotype with increased macrophage activation which is potentially associated with a more severe form of the disease. Conclusion We have identified distinct immunopathotypes in both the peripheral and local immune response of CD patients. Further investigation will correlate these distinct immune responses in CD with clinical parameters, to understand associations between diverse treatment responses and disease behaviours.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

GORKIEWICZPETKOW, A., M. BLASZCZYK, and S. JABONSKA. "P010 Skin involvement in dermatomyositis (DM)." Journal of the European Academy of Dermatology and Venereology 9 (September 1997): S155. http://dx.doi.org/10.1016/s0926-9959(97)89484-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Boudabous, H., S. Ahmed, and G. Belhabib. "P013 Neuroendocrine differenciation in bladder cancer." European Urology Supplements 12, no. 6 (November 2013): 135. http://dx.doi.org/10.1016/s1569-9056(13)62341-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Sánchez, Jonatan, Ana Talamillo, Coralia Pérez, Fernando Lopitz, Manuel Rodriguez, and Rosa Barrio. "07-P017 Sumoylation modulates Spalt activity." Mechanisms of Development 126 (August 2009): S141. http://dx.doi.org/10.1016/j.mod.2009.06.300.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Hakanen, Janne, Sébastien Duprat, and Marjo Salminen. "14-P019 Netrin1 in forebrain development." Mechanisms of Development 126 (August 2009): S245. http://dx.doi.org/10.1016/j.mod.2009.06.638.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Jakt, Lars Martin, Satoko Moriwaki, and Shinichi Nishikawa. "18-P017 Cellular parameterisation of differentiation." Mechanisms of Development 126 (August 2009): S289—S290. http://dx.doi.org/10.1016/j.mod.2009.06.784.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Poretti, A., T. A. Huisman, F. M. Cowan, E. Del Giudice, P. Y. Jeannet, D. Prayer, M. A. Rutherford, A. J. du Plessis, C. Limperopoulos, and E. Boltshauser. "P019 Cerebellar clefts: a second series." European Journal of Paediatric Neurology 13 (September 2009): S27. http://dx.doi.org/10.1016/s1090-3798(09)70077-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Paneque, M. Fajardo, C. B. Congregado Ruiz, J. M. Conde Sánchez, C. Corchuelo Maillo, I. Osmán Sánchez, J. M. Pena Outeiriño, and R. A. Medina López. "P014 Salvage robotic prostatectomy after brachytherapy." European Urology Supplements 13, no. 5 (November 2014): 112–13. http://dx.doi.org/10.1016/s1569-9056(14)61239-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Antic, D., D. Tomin, V. Cemerikic, M. Perunicic, I. Elezovic, N. Suvajdzic, M. Bakrac, J. Bila, M. Mitrovic, and D. Boskovic. "P016 Granulocytic sarcoma: single institution expirience." Leukemia Research 31 (September 2007): S71—S72. http://dx.doi.org/10.1016/s0145-2126(07)70364-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Revelo, Monica, Dylan Miller, and Neelima Kandula. "P017 Malakoplakia in heart transplant recipients." Human Immunology 80 (September 2019): 67. http://dx.doi.org/10.1016/j.humimm.2019.07.069.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Chaveles, Ioannis, Olga-Maria Kotopouli, Caroline Foster, and Charles Zammit. "P015. Patient's perception of digital mammography." European Journal of Surgical Oncology (EJSO) 41, no. 6 (June 2015): S32. http://dx.doi.org/10.1016/j.ejso.2015.03.051.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Lecouflet, M., M. Verschoore, C. Giard, P. Gohier, Y. Le Corre, D. Milea, and L. Martin. "P014. Orbital myositis associated with ipilimumab." Melanoma Research 21 (June 2011): e24. http://dx.doi.org/10.1097/01.cmr.0000399475.01484.56.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Noor, I., M. Aquino, and M. Davis-Lorton. "P017 Induction of tolerance to temozolamide." Annals of Allergy, Asthma & Immunology 119, no. 5 (November 2017): S21—S22. http://dx.doi.org/10.1016/j.anai.2017.08.086.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Yang, Liu, Shuqing Chen, Fan Mo, Zheling Chen, Jiahong Jiang, Shanshan Zhang, Ning Han, et al. "A peptide-based neoantigen vaccine for patients with advanced pancreatic cancer refractory to standard treatment." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e14563-e14563. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14563.

Повний текст джерела

Анотація:

e14563 Background: Tumor-specific neoantigens are considered as personalized and potential ultimate targets for cancer immunotherapy. Recently, neoantigen cancer vaccines have been designed to train the patient's immune system to specifically target and kill tumor cells. However, the safety and efficacy of neoantigen vaccines in pancreatic cancer treatment remain poorly understood. Methods: Personalized peptide neoantigen cancer vaccines were successfully designed and manufactured for pancreatic cancers with low tumor mutation burden. Seven patients with advanced pancreatic cancer refractory to standard treatments were enrolled and treated with personalized peptide neoantigen vaccine, iNeo-Vac-P01. Besides the evaluation of the safety and clinical efficacy of iNeo-Vac- P01, pre- and post-vaccination peripheral blood samples were collected to analyze the vaccine’s immunogenicity. Results: For all 7 patients, none sever vaccine-related adverse effects was witnessed. The mean progression free survival, overall survival (OS) and OS associated with vaccine treatment were 3.1, 24.1 and 8.3 months, respectively. For Patient P01, who had a 21-month OS associated with vaccine treatment, the abundance of the TCR clone remarkably increased after vaccination, indicating the potential of iNeo-Vac-P01 to specifically induce a subset of T cells to kill tumor cells. This study also demonstrated that the quantity of IFN-γ in peripheral blood might be a potential biomarker for OS. Conclusions: We believed that it was the first tentative study focused in the application of peptide-based neoantigen cancer vaccine in advanced pancreatic cancer. Promisingly, personalized peptide neoantigen vaccine might provide a new strategy to improve the limited clinical efficacy for pancreatic cancer. Clinical trial information: NCT03645148.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

George, M., A. Khan, J. Nicholls, and M. S. Thambirajah. "P01-202 - School refusal." European Psychiatry 25 (2010): 412. http://dx.doi.org/10.1016/s0924-9338(10)70408-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Roque, M., P. Carriço, and I. Morais. "P01-373 - Neuroticizing MCI." European Psychiatry 25 (2010): 586. http://dx.doi.org/10.1016/s0924-9338(10)70581-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Perlov, J., and A. Sawyer. "P01-342-Almost autism." European Psychiatry 26, S2 (March 2011): 344. http://dx.doi.org/10.1016/s0924-9338(11)72053-3.

Повний текст джерела

Анотація:

IntroductionThe hallmark social deficits of ASD are:1.Poor eye contact2.Limited emotional, facial and voice expression3.Deficits in joint attention including deficits in showing and seeking recognition4.Deficits in mutual enjoyment5.Deficits in reading body languageThese social deficits can be difficult to identify and to define even by trained clinicians, especially when there are multiple diagnoses, and other psychiatric disorders may have/mimic these social deficits.Some of the social deficits characteristic of an ASD are found in conditions that are not ASD. The social deficits found in some children with ADHD are amplfied when the ADHD is co-morbid with Social Anxiety disorders, Language disorders, OCD and/or Global Developmental Delay, making these children look “almost autistic”.ObjectiveTo demonstrate the difficulty in trying to differentiate the “almost autistic” child from a child with ASD.AimTo stimulate discussion over the difficulty of diagnosing ASD and differentiating ASD from other childhood psychiatric disorders.MethodA Poster presentation with a video has been developed demonstrating “difficult to diagnose” children, and raising the alternative diagnoses.ResultsThe distinction between ADHD, ASD, and other disorders and not clearConclusionsThe prevalence of ASD has mushroomed in the last 20 years, partly because of greater awareness, but also because of criteria have been diffused to include other diagnostic groups. Until better diagnostic approaches occur, the clinician is dependent on observational strategies to make the diagnosis of ASD. Given the importance of the diagnosis, better techniques for diagnosis is required.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Campos, Thaiane Da Silva Teixeira, and Birgit Harter-Marques. "INSETOS BENTÔNICOS COMO INDICADORES DA QUALIDADE DA ÁGUA EM ÁREAS REABILITADAS APÓS MINERAÇÃO DE CARVÃO NO SUL DE SANTA CATARINA, BRASIL." Tecnologia e Ambiente 25 (October 7, 2019): 247. http://dx.doi.org/10.18616/ta.v25i0.3483.

Повний текст джерела

Анотація:

A qualidade dos recursos naturais no sul catarinense sofreu um impacto negativo com a atividade mineradora do carvão no final do século XIX. Projetos de recuperação ambiental estão sendo implantados há quase uma década, modificando o cenário da qualidade ambiental na região. O objetivo deste trabalho foi verificar se o processo de reabilitação das áreas degradadas resulta em uma melhora na qualidade da água, utilizando os insetos bentônicos como indicadores. As coletas da fauna aquática foram realizadas na sub-bacia do rio Fiorita, Siderópolis, SC, mensalmente, durante o período de fev./2011 a jan./2012, em três pontos (P01, P02 e P03). O P01 se encontra em áreas que não sofrerem influência ambiental, mantendo as condições naturais da água; o P02 esta localizado em uma área reabilitada e o P03 em uma área degradada. Os insetos foram coletados com o uso de rede entomológica súrber e identificados até nível de família. Os resultados obtidos comprovaram o sucesso do processo da reabilitação ambiental, de maneira que o P01 teve a maior riqueza e abundância; o P02 uma riqueza satisfatória, que respondeu as expectativas do presente estudo, enquanto o P03 obteve riqueza e abundância muito baixa.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Choi, Kati, Rashmi Samdani, Gladis Shuttlesworth, and Yinghong Wang. "P016 CASE SERIES: IMMUNOTHERAPY-INDUCED LYMPHOCYTIC COLITIS." Gastroenterology 154, no. 1 (January 2018): S9. http://dx.doi.org/10.1053/j.gastro.2017.11.048.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Ortiz-Masia, D., P. Salvador, D. C. Macias-Ceja, L. Gisbert-Ferrándiz, C. Hernandez, S. Calatayud, J. V. Esplugues, and D. Barrachina. "P015 Wnt10b promotes fibrosis in murine colitis." Journal of Crohn's and Colitis 11, suppl_1 (January 26, 2017): S86—S87. http://dx.doi.org/10.1093/ecco-jcc/jjx002.141.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Wyllie, Thomas. "P011 An experimental treatment for enteroviral sepsis." Archives of Disease in Childhood 104, no. 7 (June 19, 2019): e2.14-e2. http://dx.doi.org/10.1136/archdischild-2019-nppc.21.

Повний текст джерела

Анотація:

BackgroundA male infant was admitted to the neonatal unit with respiratory distress, following delivery by emergency caesarean section at 36/40 for maternal illness (viraemia). The patient’s condition deteriorated with disseminated intravascular coagulation (DIC), abnormal liver function, ascites and pleural effusions. Enteroviral sepsis was diagnosed following positive enterovirus PCR on lumbar puncture and stool sample.Summary of problemThere are no commercially available treatments for enterovirus in the UK. Following an extensive literature search, the neonatology consultant became aware of an experimental treatment with potential action against enterovirus.1 2 Pocapavir is an investigational drug candidate developed for poliovirus indications, but also has antiviral activity against nonpolio enteroviruses. The consultant was keen to exhaust every option, so reached out to the company in the US. The company (Virodefense) offered to provide the drug on a compassionate use/open label trial basis, asking that regular pharmacokinetics tests be carried out as part of the agreement to supply.Pharmacy contributionFollowing the initial contact with Virodefense, there were several challenges for the specialist pharmacist and pharmacy procurement team. Working with IDIS and Virodefense, arrangements were made for shipment of the medication to the pharmacy department. This was complicated by the urgency of the situation and the time differences involved. Pocapavir is in phase 2 clinical trial which required the MHRA to be notified to approve the importing of the drug into the country. The MHRA were quick to give a positive decision which allowed the product to be delivered direct to the hospital while IDIS handled the importing documentation. The advised dose was 25mg/kg daily, the drug came as 500 mg capsules containing 200mg of pocapavir (with 300 mg excipients).The patient (2.7 kg) required 67.5 mg daily. The pharmacy manufacturing unit packed down 170 mg capsule contents (68 mg active ingredient) into individual pots for the neonatal unit to administer. Doses were mixed with EBM and given daily for 14 days.OutcomeThe patient recovered from the acute sepsis episode. The patient was also treated with immunoglobulin and standard supportive care so it is impossible to know how much can be attributed to the pocapavir. Pharmacokinetic samples were taken as agreed. After recovering from the initial acute sepsis the patient developed hypoglycaemia between feeds. These were investigated and metabolic causes were excluded. The working diagnosis was a response to the large hit to the liver during the septic episode, although an adverse effect of pocapavir cannot be excluded. Hypoglycaemic episodes continued and the patient was still fed 3 hourly on discharge. The patient is growing and developing well, tolerating longer fasts of 6 hours without hypoglycaemia and reducing risk in the provision of parenteral nutrition for effects that could occur due to opioid toxicity. The patient has been discharged from neonatal follow up.Lessons to be learnedWhere there’s a will there’s a way! There were many barriers to overcome including regulatory, logistical and practical complications but thanks to a concerted effort from a wide variety of teams, co-ordinated by pharmacy, the patient received this treatment. Although the contribution of this experimental drug is unclear the positive outcome for a very unwell infant should be celebrated.ReferencesModlin JF. Treatment of Neonatal Enterovirus Infections. J Pediatric Infect Dis Soc 2016;5:63–64Torres-Torres S, Myers AL, Klatte M, et al. First Use of Investigational Antiviral Drug Pocapavir (V-073) for Treating Neonatal Enteroviral Sepsis. Pediatr Infect Dis J 2015;34:52–54.

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Blickstein, D., G. Sarig, A. Jabareen, K. Toledano, M. Assalia, R. Hoffman, A. Karban, and Y. Nadir. "P019: Cryofibrinogenemia with severe acrocyanosis during pregnancy." Thrombosis Research 175 (March 2019): S13. http://dx.doi.org/10.1016/s0049-3848(19)30114-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!